Real-life effectiveness of tezepelumab in severe asthma
Allergologia et Immunopathologia · 2025
DOI: 10.15586/aei.v53i2.1326 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Allergologia et Immunopathologia, 2025. Verfasst von Juan Carlos Miralles-López und 16 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Department, University General Hospital Reina Sofía, Murcia, Spain. Hauptthemen laut MEDLINE: Anti-Asthmatic Agents, Antibodies, Monoclonal, Humanized, Asthma. Die Arbeit wurde bisher 11-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Tezepelumab is a human monoclonal antibody which inhibits the cytokine thymic stromal lymphopoietin and is effective in different asthma endotypes.
Methods
This is a prospective, multicenter study of the Register of Severe Asthma of the Region of Murcia (RE-ASGRAMUR) Group performed under routine clinical practice conditions.
Results
We present a series of 57 patients who completed at least 6 months of treatment with tezepelumab. The exacerbations decreased from a baseline mean of 2.63 in the previous year to a mean annualized rate of 0.38 after 6 months of tezepelumab (85.6% decrease). The Asthma Control Test score increased by 5.3 points, and the Mini Asthma Quality of Life Questionnaire score increased by 0.94 points. Regarding lung function, we obtained a significant increase of 188 mL in forced expiratory volume in 1 s and 166 mL in forced vital capacity. Finally, type-2 (T2) biomarkers, such as eosinophils and nitric oxide, showed a significant decrease. We compared the results in patients with or without previous biological treatment as well as in patients with or without allergy sensitization, and we did not obtain significant differences in any variable.
Conclusions
Tezepelumab is an effective treatment for severe asthma, lessening exacerbations, controlling the disease, and improving quality of life and lung function in patients with and without high T2 biomarkers, regardless of previous biological treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Department, University General Hospital Reina Sofía, Murcia, Spain.
- Pulmonology Department, University General Hospital Santa Lucia, Cartagena, Murcia, Spain.
- Pulmonology Department, University Clinic Hospital Virgen de la Arrixaca, Murcia, Spain.
- Pulmonology Department, University General Hospital Los Arcos, San Javier, Murcia, Spain.
- Pulmonology Department, Hospital de la Vega Lorenzo Guirao, Cieza, Murcia, Spain.
- Allergy Department, University General Hospital Santa Lucia, Cartagena, Murcia, Spain.
Zitieren
APA
Miralles-López, J. C., Bravo-Gutierrez, F. J., Andújar-Espinosa, R., Castilla-Martínez, M., Díaz-Chantar, C., Ramírez-Hernández, M., Cabrejos-Perotti, S., Avilés-Inglés, M. J., Ibarra-Calabuig, I., Reyes-Cotes, M. H., Pajarón-Fernández, M. J., Bernabéu-Mora, R., Alcalde-Rumayor, C., Alemany-Francés, M. L., Valverde-Molina, J., Pérez-Fernández, V., & RE-ASGRAMUR Group (2025). Real-life effectiveness of tezepelumab in severe asthma. Allergologia et Immunopathologia. https://doi.org/10.15586/aei.v53i2.1326
Vancouver
Miralles-López JC, Bravo-Gutierrez FJ, Andújar-Espinosa R, Castilla-Martínez M, Díaz-Chantar C, Ramírez-Hernández M, et al. Real-life effectiveness of tezepelumab in severe asthma. Allergologia et Immunopathologia. 2025. doi:10.15586/aei.v53i2.1326
BibTeX
@article{MirallesLpez2025,
author = {Miralles-López, Juan Carlos and Bravo-Gutierrez, Francisco-José and Andújar-Espinosa, Rubén and Castilla-Martínez, Manuel and Díaz-Chantar, Cayetano and Ramírez-Hernández, Mercedes and Cabrejos-Perotti, Sheila and Avilés-Inglés, Maria Jesús and Ibarra-Calabuig, Inmaculada and Reyes-Cotes, Miguel Henrique and Pajarón-Fernández, Manuel José and Bernabéu-Mora, Roberto and Alcalde-Rumayor, Consuelo and Alemany-Francés, María Loreto and Valverde-Molina, José and Pérez-Fernández, Virginia and RE-ASGRAMUR Group, RE-ASGRAMUR Group},
title = {Real-life effectiveness of tezepelumab in severe asthma},
journal = {Allergologia et Immunopathologia},
year = {2025},
doi = {10.15586/aei.v53i2.1326}
}
EUVIMED